Krystal Biotech, Inc.
KRYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $3 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 473% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.1% | 93.9% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 37.8% | -180.1% | – | – |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 30.7% | 21.6% | – | – |
| EPS Diluted | 3 | 0.39 | -5.49 | -3.13 |
| % Growth | 669.2% | 107.1% | -75.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |